N-苯甲酰基邻氨基苯甲酸衍生物作为醛酮还原酶 AKR1C3 的选择性抑制剂。
N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
机构信息
Institute of Biochemistry, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
出版信息
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5948-51. doi: 10.1016/j.bmcl.2012.07.062. Epub 2012 Jul 22.
Abstract
Human aldo-keto reductases AKR1C1-AKR1C3 are involved in the biosynthesis and inactivation of steroid hormones and prostaglandins and thus represent attractive targets for the development of new drugs. We synthesized a series of N-benzoyl anthranilic acid derivatives and tested their inhibitory activity on AKR1C enzymes. Our data show that these derivatives inhibit AKR1C1-AKR1C3 isoforms with low micromolar potency. In addition, five selective inhibitors of AKR1C3 were identified. The most promising inhibitors were compounds 10 and 13, with IC(50) values of 0.31 μM and 0.35 μM for AKR1C3, respectively.
摘要
人醛酮还原酶 AKR1C1-AKR1C3 参与甾体激素和前列腺素的生物合成和失活，因此代表了开发新药的有吸引力的靶标。我们合成了一系列 N-苯甲酰邻氨基苯甲酸衍生物，并测试了它们对 AKR1C 酶的抑制活性。我们的数据表明，这些衍生物以低微摩尔的效力抑制 AKR1C1-AKR1C3 同工酶。此外，还鉴定了五种 AKR1C3 的选择性抑制剂。最有前途的抑制剂是化合物 10 和 13，它们对 AKR1C3 的 IC50 值分别为 0.31 μM 和 0.35 μM。
相似文献
1
N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.N-苯甲酰基邻氨基苯甲酸衍生物作为醛酮还原酶 AKR1C3 的选择性抑制剂。
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5948-51. doi: 10.1016/j.bmcl.2012.07.062. Epub 2012 Jul 22.
2
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.通过生物电子等排体骨架跃迁方法发现的羟基三唑衍生物作为强效和选择性醛酮还原酶1C3（AKR1C3）抑制剂。
Eur J Med Chem. 2017 Oct 20;139:936-946. doi: 10.1016/j.ejmech.2017.08.046. Epub 2017 Aug 24.
3
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.基于 N-苯基-氨基苯甲酸酯的醛酮还原酶 1C3（型 5 17β-羟甾脱氢酶）的高效和选择性抑制剂的开发及其构效关系。
J Med Chem. 2012 Mar 8;55(5):2311-23. doi: 10.1021/jm201547v. Epub 2012 Feb 15.
4
2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).2,3-二芳基丙烯酸作为 5 型 17β-羟甾脱氢酶（AKR1C3）的选择性非甾体抑制剂。
Eur J Med Chem. 2013 Apr;62:89-97. doi: 10.1016/j.ejmech.2012.12.045. Epub 2013 Jan 3.
5
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.一种消炎痛类似物，N-(4-氯苯甲酰基)-褪黑素，是醛糖酮还原酶1C3（2型3α-羟基类固醇脱氢酶、5型17β-羟基类固醇脱氢酶和前列腺素F合酶）的选择性抑制剂，醛糖酮还原酶1C3是治疗激素依赖性和非激素依赖性恶性肿瘤的潜在靶点。
Biochem Pharmacol. 2008 Jan 15;75(2):484-93. doi: 10.1016/j.bcp.2007.09.008. Epub 2007 Sep 14.
6
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.通过片段文库的虚拟筛选发现的醛酮还原酶 AKR1C1 和 AKR1C3 的选择性抑制剂。
J Med Chem. 2012 Sep 13;55(17):7417-24. doi: 10.1021/jm300841n. Epub 2012 Aug 27.
7
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.发现(R)-2-(6-甲氧基萘-2-基)丁酸作为一种强效且选择性的醛酮还原酶1C3抑制剂。
J Med Chem. 2016 Aug 25;59(16):7431-44. doi: 10.1021/acs.jmedchem.6b00160. Epub 2016 Aug 12.
8
Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.合成作为醛酮还原酶1C3选择性强效抑制剂的巴卡里宁非异戊二烯类似物。
Bioorg Med Chem. 2014 Oct 1;22(19):5220-33. doi: 10.1016/j.bmc.2014.08.007. Epub 2014 Aug 14.
9
New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.新型环戊烷衍生物作为类固醇代谢酶AKR1C1和AKR1C3的抑制剂
Eur J Med Chem. 2009 Jun;44(6):2563-71. doi: 10.1016/j.ejmech.2009.01.028. Epub 2009 Feb 5.
10
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.5 型 17β-羟甾脱氢酶（AKR1C3）抑制剂：概述和结构见解。
J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16.
引用本文的文献
1
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.醛酮还原酶（AKR）1C3抑制剂：专利综述
Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. doi: 10.1080/13543776.2017.1379503. Epub 2017 Sep 19.
2
Precursor-Directed Combinatorial Biosynthesis of Cinnamoyl, Dihydrocinnamoyl, and Benzoyl Anthranilates in Saccharomyces cerevisiae.酿酒酵母中肉桂酰、二氢肉桂酰和苯甲酰邻氨基苯甲酸酯的前体导向组合生物合成
PLoS One. 2015 Oct 2;10(10):e0138972. doi: 10.1371/journal.pone.0138972. eCollection 2015.
3
Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).筛选糖精类似物作为5型17β-羟基类固醇脱氢酶（AKR1C3）的选择性抑制剂。
Chem Biol Interact. 2015 Jun 5;234:339-48. doi: 10.1016/j.cbi.2014.12.015. Epub 2014 Dec 31.
4
AKR1C3 as a target in castrate resistant prostate cancer.AKR1C3 作为去势抵抗性前列腺癌的靶点。
J Steroid Biochem Mol Biol. 2013 Sep;137:136-49. doi: 10.1016/j.jsbmb.2013.05.012. Epub 2013 Jun 6.
5
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.开发强效和选择性的吲哚美辛类似物，用于抑制去势抵抗性前列腺癌中的 AKR1C3（5 型 17β-羟甾脱氢酶/前列腺素 F 合酶）。
J Med Chem. 2013 Mar 28;56(6):2429-46. doi: 10.1021/jm3017656. Epub 2013 Mar 13.
本文引用的文献
1
2
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.AKR1C3 晶体结构包含 N-(芳基)氨基苯甲酸酯抑制剂和双功能 AKR1C3 抑制剂及雄激素受体拮抗剂。用于去势抵抗性前列腺癌的治疗靶点。
Bioorg Med Chem Lett. 2012 May 15;22(10):3492-7. doi: 10.1016/j.bmcl.2012.03.085. Epub 2012 Mar 29.
3
Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.醛酮还原酶 AKR1C1-AKR1C4 的抑制剂。
Curr Med Chem. 2011;18(17):2554-65. doi: 10.2174/092986711795933713.
4
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).发现取代的 3-(苯基氨基)苯甲酸作为 5 型 17β-羟甾脱氢酶 (AKR1C3) 的有效和选择性抑制剂。
Bioorg Med Chem Lett. 2011 Mar 1;21(5):1464-8. doi: 10.1016/j.bmcl.2011.01.010. Epub 2011 Jan 7.
5
Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.醛酮还原酶 AKR1C1、AKR1C2 和 AKR1C3 可能增强卵巢子宫内膜异位症中的孕激素代谢。
Chem Biol Interact. 2011 May 30;191(1-3):217-26. doi: 10.1016/j.cbi.2011.01.003. Epub 2011 Jan 11.
6
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.AKR1C3 表达水平升高可促进前列腺癌细胞的存活和前列腺细胞介导的内皮细胞管形成：对前列腺癌进展的影响。
BMC Cancer. 2010 Dec 6;10:672. doi: 10.1186/1471-2407-10-672.
7
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.5 型 17β-羟甾脱氢酶（AKR1C3）抑制剂：概述和结构见解。
J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16.
8
The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.醛酮还原酶超家族及其在药物代谢和解毒中的作用。
Drug Metab Rev. 2008;40(4):553-624. doi: 10.1080/03602530802431439.
9
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.AKR1C2和AKR1C3介导的前列腺素D2代谢增强了人前列腺癌细胞中的PI3K/Akt增殖信号通路。
Mol Cell Endocrinol. 2008 Jul 16;289(1-2):60-6. doi: 10.1016/j.mce.2008.04.004. Epub 2008 Apr 22.
10
Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.甾体内酯作为5型17β-羟基类固醇脱氢酶的抑制剂：化学合成、酶抑制活性以及雌激素和雄激素活性评估
Eur J Med Chem. 2009 Feb;44(2):632-44. doi: 10.1016/j.ejmech.2008.03.020. Epub 2008 Apr 8.
Zotero 插件